Ser396

Site Information
GAEIVyKsPVVsGDt SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 449081

In vivo Characterization
Methods used to characterize site in vivo:	2D analysis ( 105 , 107 ) , electrophoretic mobility shift ( 85 ) , immunoassay ( 8 , 11 , 18 , 22 , 27 , 28 , 29 , 33 , 35 , 42 , 53 ) , immunoprecipitation ( 13 , 16 , 26 , 40 ) , mass spectrometry ( 9 , 13 , 17 , 18 , 39 , 57 , 59 , 71 , 76 , 89 , 105 ) , mass spectrometry (in vitro) ( 37 ) , microscopy-colocalization with upstream kinase ( 98 ) , modification-specific antibody ( 16 , 39 , 40 , 59 ) , mutation of modification site ( 13 , 16 , 26 , 40 , 43 , 62 , 63 , 65 , 70 , 83 , 85 , 110 ) , peptide sequencing ( 97 ) , phospho-antibody ( 6 , 7 , 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 58 , 59 , 63 , 64 , 66 , 67 , 68 , 69 , 71 , 72 , 73 , 74 , 77 , 78 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 91 , 93 , 94 , 95 , 96 , 98 , 100 , 101 , 103 , 106 , 109 , 110 ) , western blotting ( 6 , 7 , 10 , 12 , 13 , 14 , 15 , 16 , 19 , 20 , 21 , 23 , 24 , 25 , 26 , 28 , 30 , 31 , 32 , 34 , 35 , 36 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 48 , 50 , 52 , 53 , 54 , 55 , 56 , 58 , 63 , 64 , 65 , 67 , 68 , 69 , 72 , 74 , 77 , 78 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 88 , 91 , 95 , 97 , 98 , 103 , 105 , 106 , 109 , 110 )
Disease tissue studied:	Alzheimer's disease ( 9 , 47 , 51 , 56 , 57 , 63 , 64 , 66 , 67 , 68 , 76 , 84 , 98 , 100 , 105 ) , adrenal cancer ( 62 , 93 ) , pheochromocytoma ( 62 , 93 ) , brain cancer ( 98 ) , glioma ( 98 ) , neuroblastoma ( 10 , 11 , 15 , 16 , 18 , 20 , 23 , 24 , 25 , 29 , 30 , 34 , 36 , 41 , 78 , 80 , 85 , 103 , 106 , 107 ) , melanoma skin cancer ( 58 ) , diabetes mellitus ( 67 ) , type 2 diabetes ( 67 ) , PSP ( 71 , 88 )
Relevant cell line - cell type - tissue:	'brain, brainstem' ( 72 , 95 ) , 'brain, caudate-putamen' ( 88 ) , 'brain, cerebellum' ( 68 ) , 'brain, cerebral cortex' ( 22 , 35 , 43 , 84 , 88 , 89 , 95 ) , 'brain, embryonic' ( 109 ) , 'brain, hippocampus' ( 13 , 30 , 43 , 72 , 101 ) , 'brain, hippocampus, CA1 region' ( 33 ) , 'brain, hippocampus, dentate gyrus' ( 44 ) , 'brain, striatum' ( 88 ) , 'neuron, cortical' ( 32 , 74 ) , 'neuron, cortical'-brain ( 54 ) , 'neuron, hippocampal, CA1 pyramidal' ( 35 ) , 'neuron, striatal'-brain ( 54 ) , 293 (epithelial) ( 12 , 20 , 32 , 43 , 45 , 48 , 52 , 53 , 56 , 65 , 69 , 83 , 94 ) , 3T3 (fibroblast) ( 31 ) , astrocyte ( 14 , 42 ) , brain ( 7 , 27 , 39 , 45 , 47 , 50 , 55 , 57 , 59 , 67 , 71 , 76 , 91 , 105 , 109 , 110 ) , brain [Tau iso8 (human)] ( 77 , 82 ) , C8D1A (astrocyte) ( 14 ) , cerebrospinal fluid ( 9 , 100 ) , CHO (fibroblast) [Tau (human), transfection] ( 107 ) , CHO (fibroblast) [Tau iso8 (human)] ( 81 ) , CHO (fibroblast) ( 62 , 64 , 78 , 86 , 97 , 110 ) , colon ( 8 ) , COS (fibroblast) ( 84 , 85 ) , E.coli (bacterial) ( 37 , 70 ) , fibroblast ( 21 ) , H4 (glial) ( 98 ) , HEK293T (epithelial) ( 13 , 40 , 46 ) , HeLa (cervical) ( 58 , 73 ) , LAN-5 (neural crest) ( 106 , 107 ) , microglia ( 42 ) , Neuro-2a (neuron) ( 23 , 106 ) , neuron ( 6 , 19 , 20 , 26 , 42 ) , neuron-'brain, cerebral cortex' ( 51 ) , neuron-'brain, hippocampus' ( 35 , 40 , 43 , 58 , 63 , 66 , 85 ) , neuron-brain ( 28 ) , NPC (neural crest) ( 42 ) , PC-12 (chromaffin) ( 62 , 93 ) , SH-SY5Y (neural crest) ( 10 , 11 , 15 , 16 , 18 , 20 , 23 , 24 , 25 , 29 , 30 , 34 , 36 , 41 , 78 , 80 , 85 , 87 , 103 ) , spinal cord ( 44 )

Upstream Regulation
Regulatory protein:	AKAP9 (human) ( 18 ) , APP (human) ( 72 ) , ATG5 (human) ( 24 ) , CASP6 (human) ( 35 ) , CDC37 (human) ( 58 ) , CDK5R1 (mouse) ( 95 ) , Diminuto (human) ( 14 , 34 , 36 ) , ERK5 (human) ( 103 ) , JNK1 (human) ( 85 , 97 ) , MEK5 (human) ( 103 ) , p300 (human) ( 16 ) , P38B (human) ( 13 ) , P38G (human) ( 13 , 103 ) , PTPRA (human) ( 53 ) , RASD1 (human) ( 69 ) , RXRA (mouse) ( 81 ) , SET (human) ( 40 ) , SET (mouse) ( 43 ) , SGK1 (human) ( 30 ) , SPAG5 (human) ( 73 ) , Tau iso8 (human) ( 63 , 78 , 82 ) , TEBP (human) ( 58 )
Putative in vivo kinases:	CDK5 (mouse) ( 95 ) , CK1D (human) ( 94 ) , DYRK1A (human) ( 46 ) , ERK1 (human) ( 14 ) , ERK2 (human) ( 14 ) , GSK3A (human) ( 65 ) , GSK3B (human) ( 10 , 12 , 31 , 32 , 34 , 64 , 65 , 73 , 85 ) , JNK1 (human) ( 85 ) , P38A (human) ( 13 )
Kinases, in vitro:	AMPKA1 (human) ( 60 ) , CAMK2A (rat) ( 108 ) , CDK2 (human) ( 37 ) , CDK5 (human) ( 79 , 99 , 102 ) , CK1D (human) ( 94 ) , DYRK1A (human) ( 46 ) , DYRK1A (rat) ( 75 ) , ERK1 (human) ( 107 ) , ERK2 (human) ( 107 ) , GSK3A (cow) ( 108 ) , GSK3B (human) ( 13 , 37 , 61 , 75 , 79 , 90 , 99 , 104 ) , MARK1 (human) ( 60 ) , P38A (human) ( 13 ) , P38D (human) ( 103 ) , P38G (human) ( 103 ) , PKCA (rat) ( 108 )
Putative upstream phosphatases:	PPP2CA (human) ( 12 , 34 )
Phosphatases, in vitro:	PPP2CA (human) ( 64 )
Treatments:	(E)-4-(3-(2-(5-nitroquinolin-2-yl)vinyl)quinolin-2-yl)morpholine ( 15 ) , 2-(pyridin-4-yl)-4-(p-tolyl)quinoline ( 15 ) , 24r ( 11 ) , 27g ( 11 ) , 2JY-OBZ4 ( 12 ) , AlCl3 ( 23 ) , anisomycin ( 103 ) , apilimod ( 28 ) , arsenite ( 97 ) , ATG1 ( 7 ) , beta-amyloid_25-35 ( 10 , 25 ) , chloroquine ( 86 ) , colforsin ( 56 ) , DES ( 34 ) , development ( 7 , 77 ) , dexamethasone ( 30 ) , DIPQUO ( 31 ) , donepezil ( 11 ) , doxycycline ( 98 ) , EMD638683 ( 30 ) , FK506 ( 77 ) , ginkgolic acid ( 48 ) , glyceraldehyde ( 11 , 29 ) , GW_9662 ( 81 ) , high-fat diet ( 30 ) , high_glucose ( 30 ) , huperzine_A ( 12 ) , IC261 ( 94 ) , JNK_inhibitor_I ( 81 ) , JQ1 ( 19 ) , kenpaullone ( 97 ) , KYP-2047 ( 6 ) , lithium ( 10 , 25 , 73 , 74 , 80 , 85 , 87 , 97 ) , low_glucose ( 93 ) , LY294002 ( 81 ) , macelignan ( 20 ) , MG132 ( 23 , 86 ) , MK-591 ( 55 ) , MOS ( 32 ) , mutation ( 92 ) , myricetin ( 24 ) , nocodazole ( 85 ) , okadaic_acid ( 53 , 56 , 74 , 93 , 97 ) , olomoucine ( 97 ) , PD98059 ( 87 ) , pioglitazone ( 81 ) , PUGNAc ( 93 ) , rolipram ( 18 , 45 ) , SAD-2 ( 11 ) , SAD-6 ( 11 ) , SB202190 ( 103 ) , SB203580 ( 85 , 97 ) , SB216763 ( 80 ) , SB415286 ( 15 ) , seliciclib ( 85 , 97 ) , siRNA ( 31 , 69 ) , sorbitol ( 103 ) , SP600125 ( 85 ) , staurosporine ( 103 ) , streptozotocin ( 93 ) , T0070907 ( 81 ) , tanespimycin ( 86 ) , taxol ( 85 ) , tideglusib ( 29 ) , triciribine ( 81 ) , troglitazone ( 81 ) , tungstate ( 87 ) , U0126 ( 14 , 31 , 97 ) , W5 ( 25 ) , wortmannin ( 81 ) , XJP-1 ( 11 )

Downstream Regulation
Effects of modification on Tau iso8:	intracellular localization ( 98 ) , molecular association, regulation ( 83 , 92 , 94 , 101 , 102 , 110 ) , O-GlcNAc glycosylation ( 68 ) , phosphorylation ( 83 ) , protein conformation ( 37 , 56 , 70 ) , protein processing ( 90 )
Effects of modification on biological processes:	apoptosis, induced ( 24 ) , autophagy, inhibited ( 36 ) , cell differentiation, inhibited ( 31 ) , cell growth, inhibited ( 34 ) , cytoskeletal reorganization ( 70 , 75 , 83 , 98 , 101 , 102 , 110 )
Induce interaction with:	Tau iso8 (human) ( 83 , 92 )
Inhibit interaction with:	TUBA1A (cow) ( 102 ) , TUBA4A (human) ( 83 ) , TUBB (cow) ( 102 ) , TUBB (human) ( 110 )

Disease / Diagnostics Relevance
Relevant diseases:	Alzheimer's disease ( 9 , 21 , 22 , 33 , 35 , 42 , 44 , 49 , 54 , 57 , 66 , 67 , 68 , 70 , 100 , 101 , 105 , 110 ) , ALS ( 109 ) , AGD ( 27 ) , CTE ( 22 ) , DLB ( 54 ) , type 2 diabetes ( 30 , 67 ) , Down syndrome ( 49 ) , Parkinson's disease ( 54 , 109 ) , PSP ( 71 )

References
1	Hartnell IJ, et al. (2024) Glial reactivity and T cell infiltration in frontotemporal lobar degeneration with tau pathology. Brain 147, 590-606 37703311 Curated Info
2	Chu Y, et al. (2024) Nigrostriatal tau pathology in parkinsonism and Parkinson's disease. Brain 147, 444-457 38006313 Curated Info
3	Nuñez-Diaz C, et al. (2024) The fluorescent ligand bTVBT2 reveals increased p-tau uptake by retinal microglia in Alzheimer's disease patients and App mice. Alzheimers Res Ther 16, 4 38167557 Curated Info
4	Zhang X, et al. (2023) Soluble TREM2 ameliorates tau phosphorylation and cognitive deficits through activating transgelin-2 in Alzheimer's disease. Nat Commun 14, 6670 37865646 Curated Info
5	Isei MO, et al. (2023) Site-specific phosphorylation of tau impacts mitochondrial function and response to stressors. J Neurochem 37787052 Curated Info
6	Eteläinen TS, et al. (2023) A prolyl oligopeptidase inhibitor reduces tau pathology in cellular models and in mice with tauopathy. Sci Transl Med 15, eabq2915 37043557 Curated Info
7	Chatterjee S, et al. (2023) Age-related changes in tau and autophagy in human brain in the absence of neurodegeneration. PLoS One 18, e0262792 36701399 Curated Info
8	Chapelet G, et al. (2023) Tau expression and phosphorylation in enteroendocrine cells. Front Neurosci 17, 1166848 37332860 Curated Info
9	Gobom J, et al. (2022) Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum. Mol Neurodegener 17, 81 36510321 Curated Info
10	Yan N, et al. (2022) Synthesis and biological evaluation of thieno[3,2-]pyrazol-3-amine derivatives as potent glycogen synthase kinase 3β inhibitors for Alzheimer's disease. J Enzyme Inhib Med Chem 37, 1724-1736 35698879 Curated Info
11	Uras G, et al. (2022) Development of p-Tau Differentiated Cell Model of Alzheimer's Disease to Screen Novel Acetylcholinesterase Inhibitors. Int J Mol Sci 23 36499118 Curated Info
12	Guo Q, et al. (2022) Novel small molecular compound 2JY-OBZ4 alleviates AD pathology in cell models via regulating multiple targets. Aging (Albany NY) 14, 8077-8094 36227154 Curated Info
13	Stefanoska K, et al. (2022) Alzheimer's disease: Ablating single master site abolishes tau hyperphosphorylation. Sci Adv 8, eabl8809 35857446 Curated Info
14	Mai M, et al. (2022) DHCR24 Knockdown Induces Tau Hyperphosphorylation at Thr181, Ser199, Ser262, and Ser396 Sites via Activation of the Lipid Raft-Dependent Ras/MEK/ERK Signaling Pathway in C8D1A Astrocytes. Mol Neurobiol 35804281 Curated Info
15	Lin CH, et al. (2022) Virtual Screening and Testing of GSK-3 Inhibitors Using Human SH-SY5Y Cells Expressing Tau Folding Reporter and Mouse Hippocampal Primary Culture under Tau Cytotoxicity. Biomol Ther (Seoul) 31 35790892 Curated Info
16	Kim MS, et al. (2022) Tau acetylation at K280 regulates tau phosphorylation. Int J Neurosci, 1-5 35603448 Curated Info
17	Ferrer I, et al. (2022) Dysregulated Brain Protein Phosphorylation Linked to Increased Human Tau Expression in the hTau Transgenic Mouse Model. Int J Mol Sci 23 35742871 Curated Info
18	You Y, et al. (2022) Alzheimer's disease associated AKAP9 I2558M mutation alters posttranslational modification and interactome of tau and cellular functions in CRISPR-edited human neuronal cells. Aging Cell, e13617 35567427 Curated Info
19	Zhang S, et al. (2022) Degradation and inhibition of epigenetic regulatory protein BRD4 exacerbate Alzheimer's disease-related neuropathology in cell models. J Biol Chem 298, 101794 35248531 Curated Info
20	Gu L, et al. (2022) Inhibitory Effects of Macelignan on Tau Phosphorylation and Aβ Aggregation in the Cell Model of Alzheimer's Disease. Front Nutr 9, 892558 35662922 Curated Info
21	Lopez-Toledo G, et al. (2022) Patient-Derived Fibroblasts With Presenilin-1 Mutations, That Model Aspects of Alzheimer's Disease Pathology, Constitute a Potential Object for Early Diagnosis. Front Aging Neurosci 14, 921573 35847683 Curated Info
22	Stathas S, et al. (2021) Tau phosphorylation sites serine202 and serine396 are differently altered in chronic traumatic encephalopathy and Alzheimer's disease. Alzheimers Dement 34854540 Curated Info
23	Pan B, et al. (2021) Mechanism by Which Aluminum Regulates the Abnormal Phosphorylation of the Tau Protein in Different Cell Lines. ACS Omega 6, 31782-31796 34870001 Curated Info
24	Dai B, et al. (2021) Myricetin slows liquid-liquid phase separation of Tau and activates ATG5-dependent autophagy to suppress Tau toxicity. J Biol Chem, 101222 34560101 Curated Info
25	Wang XX, et al. (2021) Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease. Eur J Med Chem 225, 113821 34517222 Curated Info
26	Ismael S, Sindi G, Colvin RA, Lee D (2021) Activity-dependent release of phosphorylated human tau from Drosophila neurons in primary culture. J Biol Chem 297, 101108 34473990 Curated Info
27	Samimi N, et al. (2021) Distinct phosphorylation profiles of tau in brains of patients with different tauopathies. Neurobiol Aging 108, 72-79 34536819 Curated Info
28	Bowles KR, et al. (2021) ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids. Cell 184, 4547-4563.e17 34314701 Curated Info
29	Yao H, et al. (2021) Discovery of Novel Tacrine-Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer's Disease. J Med Chem 64, 7483-7506 34024109 Curated Info
30	Elahi M, et al. (2021) High-fat diet-induced activation of SGK1 promotes Alzheimer's disease-associated tau pathology. Hum Mol Genet 30 33890983 Curated Info
31	Cook B, et al. (2021) The small molecule DIPQUO promotes osteogenic differentiation via inhibition of glycogen synthase kinase 3 β signaling. J Biol Chem, 100696 33895139 Curated Info
32	Bi D, et al. (2021) Alginate-Derived Mannuronate Oligosaccharide Attenuates Tauopathy through Enhancing Autophagy. J Agric Food Chem 69, 4438-4445 33829789 Curated Info
33	Carlomagno Y, et al. (2021) The AD tau core spontaneously self-assembles and recruits full-length tau to filaments. Cell Rep 34, 108843 33730588 Curated Info
34	Qi Z, et al. (2021) DHCR24 Knockdown Lead to Hyperphosphorylation of Tau at Thr181, Thr231, Ser262, Ser396, and Ser422 Sites by Membrane Lipid-Raft Dependent PP2A Signaling in SH-SY5Y Cells. Neurochem Res 33710538 Curated Info
35	Noël A, Foveau B, LeBlanc AC (2021) Caspase-6-cleaved Tau fails to induce Tau hyperphosphorylation and aggregation, neurodegeneration, glial inflammation, and cognitive deficits. Cell Death Dis 12, 227 33649324 Curated Info
36	Bai X, et al. (2021) DHCR24 Knock-Down Induced Tau Hyperphosphorylation at Thr181, Ser199, Thr231, Ser262, Ser396 Epitopes and Inhibition of Autophagy by Overactivation of GSK3β/mTOR Signaling. Front Aging Neurosci 13, 513605 33967735 Curated Info
37	Cantrelle FX, et al. (2021) Phosphorylation and -GlcNAcylation of the PHF-1 Epitope of Tau Protein Induce Local Conformational Changes of the C-Terminus and Modulate Tau Self-Assembly Into Fibrillar Aggregates. Front Mol Neurosci 14, 661368 34220449 Curated Info
38	Shimonaka S, et al. (2020) Asparagine residue 368 is involved in Alzheimer's disease tau strain-specific aggregation. J Biol Chem 32759167 Curated Info
39	Arakhamia T, et al. (2020) Posttranslational Modifications Mediate the Structural Diversity of Tauopathy Strains. Cell 180, 633-644.e12 32032505 Curated Info
40	Qin M, et al. (2019) SET SUMOylation promotes its cytoplasmic retention and induces tau pathology and cognitive impairments. Acta Neuropathol Commun 7, 21 30767764 Curated Info
41	Li J, Chen W, Yi Y, Tong Q (2018) miR-219-5p inhibits tau phosphorylation by targeting TTBK1 and GSK-3β in Alzheimer's disease. J Cell Biochem 120 30556160 Curated Info
42	Park J, et al. (2018) A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer's disease. Nat Neurosci 21, 941-951 29950669 Curated Info
43	Zhang Q, et al. (2018) CK2 Phosphorylating I/SET Mediates Tau Pathology and Cognitive Impairment. Front Mol Neurosci 11, 146 29760653 Curated Info
44	Le Pichon CE, et al. (2017) Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Sci Transl Med 9 28814543 Curated Info
45	Myeku N, et al. (2016) Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med 22, 46-53 26692334 Curated Info
46	Jin N, et al. (2015) Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE. J Biol Chem 290, 15219-37 25918155 Curated Info
47	Day RJ, et al. (2015) Caspase-Cleaved Tau Co-Localizes with Early Tangle Markers in the Human Vascular Dementia Brain. PLoS One 10, e0132637 26161867 Curated Info
48	Luo HB, et al. (2014) SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. Proc Natl Acad Sci U S A 111, 16586-91 25378699 Curated Info
49	Mondragón-Rodríguez S, et al. (2014) Phosphorylation of tau protein at sites Ser(396-404) is one of the earliest events in Alzheimer's disease and Down syndrome. Neuropathol Appl Neurobiol 40, 121-35 24033439 Curated Info
50	Bailey RM, et al. (2013) LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. Acta Neuropathol 126, 809-27 24113872 Curated Info
51	Yanamandra K, et al. (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402-14 24075978 Curated Info
52	Yu G, et al. (2013) Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease. Neurobiol Aging 34, 1748-58 23374587 Curated Info
53	Luo Y, et al. (2013) PTPA activates protein phosphatase-2A through reducing its phosphorylation at tyrosine-307 with upregulation of protein tyrosine phosphatase 1B. Biochim Biophys Acta 1833, 1235-43 23428800 Curated Info
54	Duka V, et al. (2013) Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases. PLoS One 8, e75025 24073234 Curated Info
55	Chu J, Lauretti E, Di Meco A, Praticò D (2013) FLAP pharmacological blockade modulates metabolism of endogenous tau in vivo . Transl Psychiatry 3, e333 24301651 Curated Info
56	Tak H, et al. (2013) Bimolecular fluorescence complementation; lighting-up tau-tau interaction in living cells. PLoS One 8, e81682 24312574 Curated Info
57	Rudrabhatla P, Jaffe H, Pant HC (2011) Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): phosphoproteomics of Alzheimer's NFTs. FASEB J 25, 3896-905 21828286 Curated Info
58	Jinwal UK, et al. (2011) The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics. J Biol Chem 286, 16976-83 21367866 Curated Info
59	Yuzwa SA, et al. (2011) Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody. Amino Acids 40, 857-68 20706749 Curated Info
60	Thornton C, et al. (2011) AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid β-peptide exposure. Biochem J 434, 503-12 21204788 Curated Info
61	Leroy A, et al. (2010) Spectroscopic studies of GSK3{beta} phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E. J Biol Chem 285, 33435-44 20679343 Curated Info
62	Alonso AD, et al. (2010) Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J Biol Chem 285, 30851-60 20663882 Curated Info
63	Bertrand J, Plouffe V, Sénéchal P, Leclerc N (2010) The pattern of human tau phosphorylation is the result of priming and feedback events in primary hippocampal neurons. Neuroscience 168, 323-34 20394726 Curated Info
64	Qian W, et al. (2010) PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis 19, 1221-9 20308788 Curated Info
65	Buescher JL, Phiel CJ (2010) A noncatalytic domain of glycogen synthase kinase-3 (GSK-3) is essential for activity. J Biol Chem 285, 7957-63 20080974 Curated Info
66	Tremblay MA, Acker CM, Davies P (2010) Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. J Alzheimers Dis 19, 721-33 20110615 Curated Info
67	Liu Y, et al. (2009) Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J Neurochem 111, 242-9 19659459 Curated Info
68	Liu F, et al. (2009) Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain 132, 1820-32 19451179 Curated Info
69	Lau KF, et al. (2008) Dexras1 interacts with FE65 to regulate FE65-amyloid precursor protein-dependent transcription. J Biol Chem 283, 34728-37 18922798 Curated Info
70	Jeganathan S, et al. (2008) Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau and generates a pathological (MC-1) conformation. J Biol Chem 283, 32066-76 18725412 Curated Info
71	Wray S, Saxton M, Anderton BH, Hanger DP (2008) Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats. J Neurochem 105, 2343-52 18315566 Curated Info
72	Terwel D, et al. (2008) Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol 172, 786-98 18258852 Curated Info
73	Cheng TS, et al. (2008) Glycogen Synthase Kinase 3 Interacts with and Phosphorylates the Spindle-associated Protein Astrin. J Biol Chem 283, 2454-2464 18055457 Curated Info
74	Meske V, Albert F, Ohm TG (2008) Coupling of mammalian target of rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2A- and glycogen synthase kinase-3 -dependent phosphorylation of Tau. J Biol Chem 283, 100-9 17971449 Curated Info
75	Liu F, et al. (2007) Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Eur J Neurosci 26, 3429-36 18052981 Curated Info
76	Hanger DP, et al. (2007) Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 282, 23645-54 17562708 Curated Info
77	Yoshiyama Y, et al. (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-51 17270732 Curated Info
78	Iliev AI, Ganesan S, Bunt G, Wouters FS (2006) Removal of pattern-breaking sequences in microtubule binding repeats produces instantaneous tau aggregation and toxicity. J Biol Chem 281, 37195-204 17008320 Curated Info
79	Liu F, et al. (2006) PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Lett 580, 6269-74 17078951 Curated Info
80	King TD, Gandy JC, Bijur GN (2006) The protein phosphatase-1/inhibitor-2 complex differentially regulates GSK3 dephosphorylation and increases sarcoplasmic/endoplasmic reticulum calcium ATPase 2 levels. Exp Cell Res 312, 3693-700 16987514 Curated Info
81	d'Abramo C, Ricciarelli R, Pronzato MA, Davies P (2006) Troglitazone, a peroxisome proliferator-activated receptor-gamma agonist, decreases tau phosphorylation in CHOtau4R cells. J Neurochem 98, 1068-77 16787414 Curated Info
82	Schindowski K, et al. (2006) Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169, 599-616 16877359 Curated Info
83	Ding H, Matthews TA, Johnson GV (2006) Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation. J Biol Chem 281, 19107-14 16687396 Curated Info
84	Zhang X, et al. (2006) Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules. FASEB J 20, 1272-4 16645045 Curated Info
85	Tatebayashi Y, et al. (2006) c-jun N-terminal kinase hyperphosphorylates R406W tau at the PHF-1 site during mitosis. FASEB J 20, 762-4 16478768 Curated Info
86	Dickey CA, et al. (2006) HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J 20, 753-5 16464956 Curated Info
87	Gómez-Ramos A, et al. (2006) Sodium tungstate decreases the phosphorylation of tau through GSK3 inactivation. J Neurosci Res 83, 264-73 16397900 Curated Info
88	Puig B, Rey MJ, Ferrer I (2005) Individual and regional variations of phospho-tau species in progressive supranuclear palsy. Acta Neuropathol (Berl) 110, 261-8 15973541 Curated Info
89	DeGiorgis JA, et al. (2005) Phosphoproteomic analysis of synaptosomes from human cerebral cortex. J Proteome Res 4, 306-15 15822905 Curated Info
90	Arai T, Guo JP, McGeer PL (2005) Proteolysis of non-phosphorylated and phosphorylated tau by thrombin. J Biol Chem 280, 5145-53 15542598 Curated Info
91	Pérez M, et al. (2005) Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation. Neuroscience 130, 339-47 15664690 Curated Info
92	Alonso Adel C, et al. (2004) Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem 279, 34873-81 15190058 Curated Info
93	Liu F, et al. (2004) O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A 101, 10804-9 15249677 Curated Info
94	Li G, Yin H, Kuret J (2004) Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules. J Biol Chem 279, 15938-45 14761950 Curated Info
95	Noble W, et al. (2003) Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-65 12765608 Curated Info
96	Grace EA, Busciglio J (2003) Aberrant activation of focal adhesion proteins mediates fibrillar amyloid beta-induced neuronal dystrophy. J Neurosci 23, 493-502 12533609 Curated Info
97	Giasson BI, et al. (2002) The environmental toxin arsenite induces tau hyperphosphorylation. Biochemistry 41, 15376-87 12484777 Curated Info
98	DeTure M, Ko LW, Easson C, Yen SH (2002) Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau. Am J Pathol 161, 1711-22 12414518 Curated Info
99	Liu F, Iqbal K, Grundke-Iqbal I, Gong CX (2002) Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett 530, 209-14 12387894 Curated Info
100	Hu YY, et al. (2002) Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol 160, 1269-78 11943712 Curated Info
101	Abraha A, et al. (2000) C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci 113 Pt 21, 3737-45 11034902 Curated Info
102	Evans DB, et al. (2000) Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau's ability to promote microtubule assembly. J Biol Chem 275, 24977-83 10818091 Curated Info
103	Jenkins SM, Zinnerman M, Garner C, Johnson GV (2000) Modulation of tau phosphorylation and intracellular localization by cellular stress. Biochem J 345 Pt 2, 263-70 10620503 Curated Info
104	Schneider A, et al. (1999) Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38, 3549-58 10090741 Curated Info
105	Hanger DP, et al. (1998) New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem 71, 2465-76 9832145 Curated Info
106	Preuss U, Mandelkow EM (1998) Mitotic phosphorylation of tau protein in neuronal cell lines resembles phosphorylation in Alzheimer's disease. Eur J Cell Biol 76, 176-84 9716264 Curated Info
107	Illenberger S, et al. (1998) The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease. Mol Biol Cell 9, 1495-512 9614189 Curated Info
108	Singh TJ, et al. (1997) Protein kinase C and calcium/calmodulin-dependent protein kinase II phosphorylate three-repeat and four-repeat tau isoforms at different rates. Mol Cell Biochem 168, 141-8 9062903 Curated Info
109	Mawal-Dewan M, et al. (1996) Identification of phosphorylation sites in PHF-TAU from patients with Guam amyotrophic lateral sclerosis/parkinsonism-dementia complex. J Neuropathol Exp Neurol 55, 1051-9 8858002 Curated Info
110	Bramblett GT, et al. (1993) Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 10, 1089-99 8318230 Curated Info